Piramal Enterprises is currently trading at Rs. 858.00, up by 14.70 points or 1.74% from its previous closing of Rs. 843.30 on the BSE.
The scrip opened at Rs. 850.00 and has touched a high and low of Rs. 861.50 and Rs. 850.00 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 875.00 on 14-Jan-2015 and a 52 week low of Rs. 508.00 on 14-Mar-2014.
Last one week high and low of the scrip stood at Rs. 875.00 and Rs. 810.00 respectively. The current market cap of the company is Rs. 14,805.00 crore.
The promoters holding in the company stood at 52.90% while Institutions and Non-Institutions held 30.51% and 16.59% respectively.
Piramal Enterprises has invested $30.65 million towards acquiring Coldstream Laboratories Inc. (Coldstream), through its wholly owned subsidiary in the USA in an all cash transaction. Of this, $5.65 million would be towards the purchase of the facility building which is currently leased to Coldstream, while the rest would be towards purchase of 100% of the company’s shares. Coldstream is a Contract Development and Manufacturing Organisation (CDMO) focused on the development and manufacturing of sterile injectable products.
Coldstream was founded in 2007 and is majority owned by University of Kentucky Research Foundation (an affiliate of the University of Kentucky). Coldstream is a specialty pharmaceutical contract manufacturer with an emphasis on clinical trial to commercial-scale manufacturing of sterile liquid and lyophilized parenterals and injectables. Coldstream has developed differentiated expertise to formulate and manufacture high potency and cytotoxic compounds including Antibody Drug Conjugates (ADCs). The company operates from a FDA approved facility located in Lexington, Kentucky, USA. Revenues of Coldstream over the last three years are $14 million (2014E), $13 million (2013) and $9 million (2012). Coldstream currently employs 91 people.
Piramal Pharma Solutions is an integrated solutions provider offering comprehensive range of services across the drug lifecycle. With a successful performance record of over four-decade in API supply (active pharmaceutical ingredients), drug products, drug discovery services, and with supply facilities in North America, Europe and Asia, it has established itself as a global market leader.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 908.70 |
| Shriram Finance | 1036.50 |
| Aditya Birla Capital | 340.20 |
| Chola Invest & Fin. | 1579.65 |
| Tata Capital | 337.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: